Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment.
Nigmatullina, Razina R
Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment. [electronic resource] - Cardiology 2009 - 277-86 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1421-9751
10.1159/000205962 doi
Adrenal Glands--physiopathology
Adrenergic beta-Antagonists--therapeutic use
Adult
Biomarkers--blood
Chronic Disease
Dihydroxyphenylalanine--blood
Disease Progression
Dopamine--blood
Epinephrine--blood
Female
Heart Failure--diagnosis
Humans
Hydroxyindoleacetic Acid--blood
Male
Middle Aged
Norepinephrine--blood
Serotonin--blood
Severity of Illness Index
Sympathetic Nervous System--physiopathology
Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment. [electronic resource] - Cardiology 2009 - 277-86 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1421-9751
10.1159/000205962 doi
Adrenal Glands--physiopathology
Adrenergic beta-Antagonists--therapeutic use
Adult
Biomarkers--blood
Chronic Disease
Dihydroxyphenylalanine--blood
Disease Progression
Dopamine--blood
Epinephrine--blood
Female
Heart Failure--diagnosis
Humans
Hydroxyindoleacetic Acid--blood
Male
Middle Aged
Norepinephrine--blood
Serotonin--blood
Severity of Illness Index
Sympathetic Nervous System--physiopathology